Search by Drug Name or NDC
NDC 59762-0540-01 Glipizide 2.5 mg/1 Details
Glipizide 2.5 mg/1
Glipizide is a ORAL TABLET, EXTENDED RELEASE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Greenstone LLC. The primary component is GLIPIZIDE.
MedlinePlus Drug Summary
Glipizide is used along with diet and exercise, and sometimes with other medications, to treat type 2 diabetes (condition in which the body does not use insulin normally and, therefore, cannot control the amount of sugar in the blood). Glipizide is in a class of medications called sulfonylureas. Glipizide lowers blood sugar by causing the pancreas to produce insulin (a natural substance that is needed to break down sugar in the body) and helping the body use insulin efficiently. This medication will only help lower blood sugar in people whose bodies produce insulin naturally. Glipizide is not used to treat type 1 diabetes (condition in which the body does not produce insulin and, therefore, cannot control the amount of sugar in the blood) or diabetic ketoacidosis (a serious condition that may occur if high blood sugar is not treated). Over time, people who have diabetes and high blood sugar can develop serious or life-threatening complications, including heart disease, stroke, kidney problems, nerve damage, and eye problems. Taking medication(s), making lifestyle changes (e.g., diet, exercise, quitting smoking), and regularly checking your blood sugar may help to manage your diabetes and improve your health. This therapy may also decrease your chances of having a heart attack, stroke, or other diabetes-related complications such as kidney failure, nerve damage (numb, cold legs or feet; decreased sexual ability in men and women), eye problems, including changes or loss of vision, or gum disease. Your doctor and other healthcare providers will talk to you about the best way to manage your diabetes.
Related Packages: 59762-0540-01Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Glipizide
Product Information
NDC | 59762-0540 |
---|---|
Product ID | 59762-0540_2b8b8b6b-c447-47ae-8e63-b8ff8c1f092c |
Associated GPIs | 27200030007505 |
GCN Sequence Number | 043463 |
GCN Sequence Number Description | glipizide TAB ER 24 2.5 MG ORAL |
HIC3 | C4K |
HIC3 Description | ANTIHYPERGLYCEMIC, INSULIN-RELEASE STIMULANT TYPE |
GCN | 50638 |
HICL Sequence Number | 000803 |
HICL Sequence Number Description | GLIPIZIDE |
Brand/Generic | Generic |
Proprietary Name | Glipizide |
Proprietary Name Suffix | XL |
Non-Proprietary Name | glipizide |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | TABLET, EXTENDED RELEASE |
Route | ORAL |
Active Ingredient Strength | 2.5 |
Active Ingredient Units | mg/1 |
Substance Name | GLIPIZIDE |
Labeler Name | Greenstone LLC |
Pharmaceutical Class | Sulfonylurea Compounds [CS], Sulfonylurea [EPC] |
DEA Schedule | n/a |
Marketing Category | NDA AUTHORIZED GENERIC |
Application Number | NDA020329 |
Listing Certified Through | 2024-12-31 |
Package
NDC 59762-0540-01 (59762054001)
NDC Package Code | 59762-0540-1 |
---|---|
Billing NDC | 59762054001 |
Package | 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (59762-0540-1) |
Marketing Start Date | 2013-05-29 |
NDC Exclude Flag | N |
Pricing Information | |
Price Per Unit | 0.1361 |
Pricing Unit | EA |
Effective Date | 2024-02-21 |
NDC Description | GLIPIZIDE XL 2.5 MG TABLET |
Pharmacy Type Indicator | C/I |
OTC | N |
Explanation Code | 1, 6 |
Classification for Rate Setting | G |
As of Date | 2024-02-21 |